10 Biotech Stocks Screaming a Buy

3. Zai Lab Limited (NASDAQ:ZLAB)

Year to Date Gain as of June 18: 50.02%

Number of Hedge Fund Holders as of Q1: 26

Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 biotech stocks screaming a buy. On June 17, the company delivered positive trial results from a preclinical study of ZL-1503, a promising IL-13/IL-31R bispecific antibody.

In the study, the IL-13/IL-31R bispecific antibody demonstrated the ability to suppress the inflammatory and pruritogenic (itch-causing) pathways in atopic dermatitis (AD). The trial results underscore the potential of ZL-1503 to act as a novel treatment option for moderate-to-severe AD.

Some key findings include a single dose of ZL-1503 (10 mg/kg, iv) completely inhibiting IL-13-mediated pSTAT6 and IL-31-induced scratching for at least 76 days. In addition, two out of three subjects exhibited prolonged IL-13-mediated pSTAT6 inhibition over 118 days. Following the positive preclinical study, Zai Lab plans to file an IND for ZL-1503 for moderate-to-severe atopic dermatitis by the end of the year.

Zai Lab Limited (NASDAQ:ZLAB) is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in oncology, immunology, neuroscience, and infectious disease.